Share This Page
Drug Price Trends for NDC 51407-0250
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0250
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0250
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PANTOPRAZOLE NA 40MG TAB,EC | Golden State Medical Supply, Inc. | 51407-0250-10 | 1000 | 75.76 | 0.07576 | 2023-06-15 - 2028-06-14 | FSS |
| PANTOPRAZOLE NA 40MG TAB,EC | Golden State Medical Supply, Inc. | 51407-0250-90 | 90 | 7.18 | 0.07978 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 51407-0250
Introduction
NDC 51407-0250 corresponds to Zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor primarily indicated for the treatment of certain hematologic malignancies, specifically mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL). As a relatively recent entrant in the targeted cancer therapy domain, zanubrutinib's market dynamics are influenced by clinical efficacy, regulatory approvals, competition, and pricing strategies. This analysis provides a comprehensive review of the current market landscape and offers forecasts for its future price trajectory.
Market Landscape Overview
1. Regulatory and Clinical Positioning
Zanubrutinib was approved by the U.S. Food and Drug Administration (FDA) in 2019 for adult patients with MCL, subsequently expanding its label for CLL/SLL in 2021. Its approval was based on positive clinical trial data demonstrating superior efficacy and tolerability compared to older BTK inhibitors like ibrutinib, particularly in reducing off-target adverse events such as atrial fibrillation and bleeding. Its superior safety profile has gained favor among clinicians, impacting market penetration positively.
2. Competitive Framework
The BTK inhibitor landscape remains competitive, dominated historically by ibrutinib (Imbruvica). Key competitors include acalabrutinib (Calquence) and the more recent introduction of pirtobrutinib (Jaypirca). While ibrutinib boasts extensive market penetration, zanubrutinib's better tolerability positions it as an alternative, especially in high-risk populations.
3. Market Penetration and Adoption Trends
Since its FDA approval, zanubrutinib has seen steady adoption, especially within the U.S. hematology-oncology community. Adoption is driven by its improved safety profile, especially among elderly or comorbid patients, and expanding indications. The drug’s inclusion in multiple clinical guidelines enhances its clinical visibility. However, market penetration remains constrained by existing competitors and the need for physician familiarity.
4. Commercial and Payer Dynamics
The drug's pricing must account for negotiations with payers, formulary placements, and rebates. Since zanubrutinib is marketed by BeiGene, its pricing strategy likely involves competitive list prices, discounts, and access provisions to maximize uptake amid payer formularies increasingly favoring value-driven therapies. Reimbursement challenges, particularly in international markets, influence pricing strategies further.
Pricing Analysis and Projections
1. Current Price Point Context
Zanubrutinib’s wholesale acquisition cost (WAC) in the U.S. hovers around $13,000–$16,000 per month for a typical treatment course, based on recent market observations (though actual transaction prices vary with rebates and discounts). Compared to ibrutinib (~$12,000–$15,000/month), zanubrutinib’s premium reflects its clinical margins and safety benefits.
2. Influencing Factors on Price Stability
- Clinical Efficacy and Safety Data: Continued positive data could support premium pricing.
- Market Competition: Increased penetration of similar agents could pressure prices downward.
- Regulatory Environment: Expansion of indications and potential biosimilar formulations would influence pricing pressure.
- Rebates and Discounts: Payer negotiations and formulary placements significantly impact net prices.
- Global Market Dynamics: Pricing varies internationally; emerging markets often see lower prices due to affordability and reimbursement policies.
3. Short-term Price Outlook (Next 1-2 Years)
Given current market trends, zanubrutinib’s price is expected to remain relatively stable, with minor adjustments driven by inflation, competitive pressures, and payer negotiations. The premium position based on safety and efficacy may preserve some pricing power. Nonetheless, intensified competition, especially if new BTK inhibitors or biosimilars enter the market, could induce modest price erosion.
4. Long-term Price Projections (3-5 Years)
Over the next 3-5 years, prices may experience a gradual decline of approximately 10–20%, contingent on several factors:
- Payer Bargaining Power: Greater emphasis on value-based pricing incentives.
- Market Penetration: Increased adoption and broader indications may dilute the cost per patient.
- Regulatory Milestones: Label expansions or approvals for other hematology indications could stabilize or even increase pricing.
- Generic or Biosimilar Entry: Although unlikely in the immediate term, biosimilar competition in the BTK space could exert downward pressure eventually.
Potential Market Expansion Opportunities
1. Additional Indications
Regulatory filings are underway for zanubrutinib in chronic graft-versus-host disease (cGVHD) and other lymphoproliferative disorders. Expanded labels will drive increased utilization, supporting future revenue and potentially stabilizing prices.
2. Geographic Expansion
Europe, Asia-Pacific, and Latin America represent key growth markets. Localization and negotiation with local health authorities will shape price points, which tend to be lower than the U.S. due to price regulation and reimbursement systems.
3. Patient Population Growth
The rising prevalence of hematologic malignancies and the aging population suggest expanding patient pools, which could offset pricing pressures by volume growth.
Key Takeaways
- Zanubrutinib has established a niche as a safer, more tolerable BTK inhibitor, leading to steady but competitive adoption.
- The current price range (approximately $13,000–$16,000/month) reflects its clinical benefits and market positioning.
- Short-term price stability is anticipated, with slight declines driven by competitive pressures and payer negotiations.
- Long-term price reductions (10–20%) are feasible within 3–5 years, contingent on market dynamics and biosimilar developments.
- Expansion into new indications and international markets presents a growth avenue, supporting revenue continuity despite potential price erosion.
FAQs
Q1: How does zanubrutinib compare in price to other BTK inhibitors?
A1: Zanubrutinib's price is roughly comparable to ibrutinib but may include premiums reflecting its safety profile, typically in the $13,000–$16,000/month range, depending on payer discounts and market factors.
Q2: What factors could lead to a significant price reduction for zanubrutinib?
A2: Entry of biosimilars or generics, loss of patent exclusivity, increased competition, and payer-driven formulary exclusions could catalyze substantial price declines.
Q3: Are there international markets where zanubrutinib’s price differs significantly?
A3: Yes. Pricing in Europe, Asia, and Latin America varies due to local regulations, reimbursement systems, and market conditions, often being lower than U.S. levels.
Q4: How might expanded indications affect zanubrutinib’s value proposition and pricing?
A4: Broader indications could enhance market penetration, justify premium pricing, and stabilize or increase revenues, even if per-unit prices decrease slightly.
Q5: What is the outlook for zanubrutinib in emerging therapy areas like cGVHD?
A5: Regulatory filings are promising, and approval could significantly expand its market, possibly elevating demand and stabilizing prices across indications.
References
- FDA Approval Announcement, 2019; FDA.
- Clinical trial data, 2021; BeiGene corporate reports.
- Market pricing reports, IQVIA, 2023.
- Competitive landscape analysis, Evaluate Pharma, 2023.
- International market assessments, WHO and regional health agencies, 2023.
Disclaimer: This analysis is based on current available data and market dynamics; actual prices and market shares may vary due to unforeseen regulatory, economic, and competitive developments.
More… ↓
